DUBLIN--(BUSINESS WIRE)--The "Vietnam Generic Drugs Market, By Type (Small Molecule Generics v/s Biosimilars), By Mode of Drug Delivery (Oral, Topical, Parenteral, Others), By Form, By Source, By Distribution Channel, By Application, By Region, Competition Forecast & Opportunities, 2027" report has been added to ResearchAndMarkets.com's offering.
Vietnam generic drugs market is projected to witness growth at a significant rate during the forecast period, 2023-2027. The market growth can be attributed to the rising demand for affordable drugs and the growing need for over-the-counter drugs against branded drugs.
One of the main factors boosting the growth of the Vietnam generic drugs market in the coming five years is the nation's quickly developing pharmaceutical industry. Sales of generic medications are surging as a result of higher pharmaceutical product demand, which is supporting the market growth. The value of pharmaceutical sales in Vietnam in 2018 was USD5.34 billion. The market for generic pharmaceuticals in Vietnam is expected to expand over the next five years due to further medical advancements and consumer desire for cost-effective pharmaceutical items.
The generic medicine market in Vietnam is considerably larger than the market for branded drugs. Branded medication sales are restricted nationwide due to stringent laws and international patent law enforcement. Therefore, the nation is dependent on the sales of generic medications, which have the same active component as they have passed the same safety tests but are marketed under other names.
Since the medications for chronic diseases are costly and typically prescribed for a longer duration, the population prefers generic drugs. Thus, the rapidly rising incidences of chronic diseases are significantly raising the demand for generic drugs. Therefore, increasing rates of conditions including diabetes, high blood pressure, and cardiovascular disease necessitate lengthy prescriptions for medications, which supports the expansion of the Vietnam generic drugs industry during the coming five years.
Key Target Audience:
- Market research and consulting firms
- Government bodies such as regulating authorities and policy makers
- Organizations, forums, and alliances
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, Vietnam generic drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Vietnam Generic Drugs Market, By Type:
- Small Molecule Generics
- Biosimilars
Vietnam Generic Drugs Market, By Mode of Drug Delivery:
- Oral
- Topical
- Parenteral
- Others
Vietnam Generic Drugs Market, By Form:
- Tablet
- Capsule
- Injection
- Others
Vietnam Generic Drugs Market, By Source:
- In House
- Contract Manufacturing Organizations
Vietnam Generic Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Vietnam Generic Drugs Market, By Application:
- Cardiovascular Diseases
- Diabetes
- Neurology
- Oncology
- Anti-Inflammatory Diseases
- Others
Vietnam Generic Drugs Market, By Region:
- Northern Region
- Central Region
- Southern Region
Key Topics Covered:
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Voice of Customer
5. Impact of COVID-19 on Vietnam Generic Drugs Market
6. Vietnam Generic Drugs Market Outlook
7. Vietnam Small Molecule Generic Drugs Market Outlook
8. Vietnam Biosimilar Generic Drugs Market Outlook
9. Market Dynamics
10. Market Trends & Developments
11. Policy & Regulatory Landscape
12. Vietnam Economic Profile
13. Competitive Landscape
14. Strategic Recommendations
Companies Mentioned
- DHG Pharmaceutical Joint Stock Company
- Traphaco Joint Stock Company
- Pymepharco Joint Stock Company
- Hatay Pharmaceutical Joint Stock Company
- Mekophar Chemical Pharmaceutical JSC
- Imexpharm Corporation
- OPC Pharmaceutical Joint Stock Company
For more information about this report visit https://www.researchandmarkets.com/r/a9g72f
